Bond.az White LogoBond.az Black Logo
→
EN ▾
AZENRU
NATO actively preparing for warPower outages in several areas of BakuMickey Rourke: From Millions to Rent"He said, we are waiting for you..." - Young man killed while waiting for his motherYouTube Surpasses NetflixWorld's Most Expensive Footballers - 2024 CIES RankingRubio's Sensational Statement on GreenlandPerez to Bring Mourinho to Real Madrid?Iran proposes 4-step plan to USFire in residential building in SumgaitNATO actively preparing for warPower outages in several areas of BakuMickey Rourke: From Millions to Rent"He said, we are waiting for you..." - Young man killed while waiting for his motherYouTube Surpasses NetflixWorld's Most Expensive Footballers - 2024 CIES RankingRubio's Sensational Statement on GreenlandPerez to Bring Mourinho to Real Madrid?Iran proposes 4-step plan to USFire in residential building in Sumgait
Personalize
Bond.az White LogoBond.az Black Logo
AZENRU
ANALYST RATINGS

Biogen Stock Rises as Stifel Maintains Buy

Biogen stock rises as Stifel maintains buy rating. Updates on Alzheimer's drug trial and financial results.

Zoe Allen
ByZoe Allen- Senior Editor
|
0
Biogen Stock Rises as Stifel Maintains Buy
Photo: Prepared by Bond.az

Stifel maintained its Buy rating and $214 price target on Biogen (BIIB) after the company announced its BIIB080 Alzheimer's drug study missed the primary endpoint.

Shares trade at $204.53, near the 52-week high. Bond.az analysis suggests the stock remains undervalued with a fair value of $258.41.

Biogen is advancing the program, citing tau PET reductions and cognitive benefit. Stifel calls this the first true test of the tau hypothesis in Alzheimer's.

More News
Legend Biotech Buy Rating Reiterated
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

ANALYST RATINGS →
0
Cogent Stock Price Target Raised to $55
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

ANALYST RATINGS →
0
H.C. Wainwright Reaffirms Mineralys Buy
2026-06-01 12:00
|
841

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

ANALYST RATINGS →
0
Goldman Sachs Upgrades Marriott Vacations Stock
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

ANALYST RATINGS →
0
Goldman Sachs Upgrades Travel + Leisure Stock to Buy
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

ANALYST RATINGS →
0
Canaccord Initiates Rare Earths Americas with Buy
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

ANALYST RATINGS →
0
BofA Raises Icon Stock Target to $125 on Bookings
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

ANALYST RATINGS →
0
RBC Capital: Sprouts faces Kroger risk
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

ANALYST RATINGS →
0
CLSA Rates Chagee Hold on Margins
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

ANALYST RATINGS →
0
Barclays Downgrades Sensata Stock on Valuation
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

ANALYST RATINGS →
0
UBS Initiates Veritone Coverage with Neutral
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

ANALYST RATINGS →
0
JMP Securities Initiates Microsoft with Outperform on AI Strategy
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

ANALYST RATINGS →
0
...
Biogen Stock Rises as Stifel Maintains Buy | Bond.az